SLN
Silence Therapeutics plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Silence Therapeutics plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No peers for Silence Therapeutics plc yet.
No peers for Silence Therapeutics plc yet.
—
No other changes.
No other changes.
Expected move
Inputsspot 19.75exp Nov 20ATM strike 20ATM straddle 0.25IV 3%
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
Linked news
News| Manager | Value | % base | |
|---|---|---|---|
| Siren | $36.4M | 14.46% | +13.74% |
| TCG Crossover | $33.3M | 13.25% | 0.00% |
| Redmile | $23.8M | 9.45% | 0.00% |
| Nantahala | $14.8M | 5.88% | −37.27% |
| Citadel | $14.6M | 5.81% | +6.70% |
| Manager | Value | % base | |
|---|---|---|---|
| Siren | $36.4M | 14.46% | +13.74% |
| TCG Crossover | $33.3M | 13.25% | 0.00% |
| Redmile | $23.8M | 9.45% | 0.00% |
| Nantahala | $14.8M | 5.88% | −37.27% |
| Citadel | $14.6M | 5.81% | +6.70% |
Silence Therapeutics plc
19.76
−0.04 · −0.20%
post 19.76 0.00%